Breaking News, Collaborations & Alliances

Isis Earns GSK Milestone

Advances HBV development program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus (HBV).   As part the alliance, Isis is discovering and developing drugs to treat HBV, which GSK has the exclusive option to in-license for further development and commercialization, following clinical proof of concept. Isis is eligible to earn pre-licensing payments and royalties on sales from any product under the alliance....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters